09:23 AM EDT, 03/18/2025 (MT Newswires) -- Can-Fite BioPharma ( CANF ) said Tuesday that the US Food and Drug Administration has approved the compassionate use treatment with anti-cancer drug Namodenoson for a pancreatic cancer patient in the US.

The clinical-stage company said it is currently evaluating Namodenoson in a late-stage clinical trial for advanced liver cancer, while it is also testing the drug in a phase 2a pancreatic cancer clinical trial in Israel.

The FDA has also granted orphan drug designation to Namodenoson, the company said.

Shares of the company rose 12% in recent Tuesday premarket activity.